Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 6436 |
| PDBID: | 8SR0 |
| Chains: | YZ_X |
| Organism: | Homo sapiens, Mus musculus |
| Method: | EM |
| Resolution (Å): | 3.53 |
| Reference: | 10.1016/j.str.2023.07.013 |
| Antibody | |
| Antibody: | favezelimab Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Human lymphocyte activation gene 3 protein (LAG-3) |
| Antigen mutation: | No |
| Durg Target: | P18627 |
Sequence information
Antibody
Heavy Chain: Y
Mutation: NULL
| >8SR0_Y|Chain B[auth H], E[auth Y]|favezelimab Fab heavy chain|Mus musculus (10090) MGWTWIFLFFLSGTAGVLSEVLLLQSGPELVKPGTSVKIPCKASGYTFTDYNVDWVKQRHGKGLEWIGDINPNNGGTIYSQKFKGKATLTVDKSSSTAFMELRSLTSEDTAVYFCARNYRWFGAMDHWGQGTSVTVSSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTAGWSHPQFEK |
Light Chain: Z
Mutation: NULL
| >8SR0_Z|Chain C[auth L], F[auth Z]|favezelimab Fab light chain|Mus musculus (10090) METDTILLWVLLLWVPGSTGDIVLTQSPASLAVSPGQRATISCKASQSLDYEGDSDMNWYQQKPGQPPRLLISGASNLESGIPARFSGSGSGTDFTVNIHPVEEEDAATYYCQQSTEDPRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKYQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: X
Mutation: NULL
| >8SR0_X|Chain A[auth D], D[auth X]|Lymphocyte activation gene 3 protein|Homo sapiens (9606) MWEAQFLGLLFLQPLWVAPVKPLQPGAEVPVVWAQEGAPAQLPCSPTIPLQDLSLLRRAGVTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPRRYTVLSVGPGGLRSGRLPLQPRVQLDERGRQRGDFSLWLRPARRADAGEYRAAVHLRDRALSCRLRLRLGQASMTASPPGSLRASDWVILNCSFSRPDRPASVHWFRNRGQGRVPVRESPHHHLAESFLFLPQVSPMDSGPWGCILTYRDGFNVSIMYNLTVLGLEPPTPLTVYAGAGSRVGLPCRLPAGVGTRSFLTAKWTPPGGGPDLLVTGDNGDFTLRLEDVSQAQAGTYTCHIHLQEQQLNATVTLAIITVTPKSFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSFSGPWLEAQEAQLLSQPWQCQLYQGERLLGAAVYFTELSSPGAQRSGRAPGALPAGHLLLFLILGVLSLLLLVTGAFGFHLWRRQWRPRRFSALEQGIHPPQAQSKIEELEQEPEPEPEPEPEPEPEPEPEQL |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| Chain residues position delta_SASA
: residuesposition Y: THR28 THR30 ASP31 TYR32 ASN33 ASP50 ASN52 ASN54 ASN55 GLY56 GLY57 THR58 ILE59 TYR100 ARG101 TRP102 PHE103 GLY104 Z: TYR31 GLU32 ASP34 ASP36 SER95 THR96 GLU97 ASP98 ARG100 X: ALA27 VAL29 GLN64 HIS65 GLN66 PRO67 ASP68 SER69 GLY70 PRO71 PRO72 SER90 SER91 ARG95 ARG97 ARG98 TYR99 THR100 GLU146 ARG148 ARG161 ARG163 LEU164 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 6 Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 6 Å from any atom.
Interacting residues (Atom distance based)
